87421067 - CYTOMX

Information

• Trademark
• 87421067

• Source

• Serial Number

  87421067

• International Classifications

  • 1 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry
  • 5 - Pharmaceutical and veterinary preparations
  • 42 - Scientific and technological services and research and design relating thereto

• Filing Date

  April 21, 2017
  7 years ago

• Transaction Date

  December 25, 2021
  3 years ago

• Status Date

  March 29, 2021
  3 years ago

• Published for Opposition Date

  December 26, 2017
  7 years ago

• Location Date

  September 20, 2018
  6 years ago

• Status Code

  606

• Current Location

  DIVISIONAL UNIT

  Employee Name

  HESIK, APRIL ANNE

• Attorney Docket Number

  S2986035

  Attorney Name

  Stephanie K. Wade

  Law Office Assigned Location Code

  N60

• Owners

  • CytomX Therapeutics, Inc.

Case File Statements

• GS0011: Biochemicals for scientific, laboratory, and research use, namely, proteolytically-activatable, protease-activatable, or proteolytically activated or protease-activated immunoglobulin and antigen-binding fragments for binding to tissue, cells and antigens; diagnostic kits for scientific, laboratory, and research use comprising proteolytically-activatable or protease-activatable, proteolytically-activated or protease-activated immunoglobulin and antigen-binding fragments for binding to tissue, cells, and antigens; immunoglobulin and antigen-binding fragments for drug conjugation and targeted cell binding for laboratory and research use; assays and reagents for use in scientific, laboratory and research purposes; biochemical test kits comprising assays and reagents for scientific, laboratory and research purposes; assay kits comprising assays and reagents for measuring, monitoring, testing and analyzing proteolytic activation and antibody binding for scientific, laboratory and research use
• GS0051: infections, inflammation; infections, inflammation; infections, inflammation; engineered cell therapies for medical purposes, namely, for use in treating cancer, infections, autoimmunity, and inflammation; infections, inflammation; assays and reagents for use in medical, medical diagnostic and therapeutic purposes for proteolytic activation and binding to tumor cells; biochemical test kits comprised of assays and reagents for medical, medical diagnostic and therapeutic purposes for proteolytic activation and binding to tumor cells; assay kits comprised of assays and reagents for measuring, monitoring, testing and analyzing proteolytic activation, antibody binding, therapeutic treatments and patient recovery for medical, medical diagnostic and therapeutic purposes; assay kits comprised of assays and reagents for use in identifying candidate patient populations for specific therapeutic treatments for medical purposes; therapeutic kits comprising proteolytically-activatable or protease-activatable, proteolytically-activated or protease-activated immunoglobulin and antigen-binding fragments for binding to tissue, cells, and antigens
• GS0421: Scientific research and development in the field of therapeutic biochemicals, engineered cell therapies and immunotherapy, oncology and dysregulated proteolytic activity; medical and scientific research and development for agents, preparations, products and technology in the field of dysregulated proteolytic activities; providing medical and scientific research information in the fields of biochemicals, engineered cell therapies, immunotherapy, oncology and dysregulated proteolytic activity; scientific investigations for medical purposes; medical research; providing scientific and medical research information and analysis relating to biochemicals, engineered cell therapies and immunotherapy, proteolytic activation, antibody binding, therapeutic treatments, patient recovery, and the identification of candidate patients for specific therapeutic treatments; testing, research, design and development services in the field of biochemicals for scientific and medical research purposes; research, design and development of assays for measuring, monitoring, testing and analyzing proteolytic activation, antibody binding, therapeutic treatments and patient recovery, and for identifying candidate patient populations for specific therapeutic treatments; providing technical support and consultation services relating to antibody selection and use, namely, providing technical scientific research consultation services; online computer services in the nature of providing a search engine for obtaining data, namely, searching, retrieving, and providing information on antibodies and research topics pertaining to antibodies on a global computer network

Case File Event Statements

• 3/29/2021 - 3 years ago

  56 - ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Type: MAB6

• 3/29/2021 - 3 years ago

  55 - ABANDONMENT - NO USE STATEMENT FILED Type: ABN6

• 8/12/2020 - 4 years ago

  54 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA

• 8/11/2020 - 4 years ago

  53 - EXTENSION 5 GRANTED Type: EX5G

• 7/29/2020 - 4 years ago

  52 - EXTENSION 5 FILED Type: EXT5

• 8/10/2020 - 4 years ago

  51 - CASE ASSIGNED TO INTENT TO USE PARALEGAL Type: AITU

• 8/3/2020 - 4 years ago

  50 - CASE ASSIGNED TO INTENT TO USE PARALEGAL Type: AITU

• 7/29/2020 - 4 years ago

  49 - TEAS EXTENSION RECEIVED Type: EEXT

• 2/7/2020 - 4 years ago

  48 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA

• 2/5/2020 - 4 years ago

  47 - EXTENSION 4 GRANTED Type: EX4G

• 2/5/2020 - 4 years ago

  46 - EXTENSION 4 FILED Type: EXT4

• 2/5/2020 - 4 years ago

  45 - TEAS EXTENSION RECEIVED Type: EEXT

• 1/30/2020 - 4 years ago

  44 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA

• 1/30/2020 - 4 years ago

  43 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP

• 1/21/2020 - 4 years ago

  42 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA

• 1/21/2020 - 4 years ago

  41 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP

• 10/16/2019 - 5 years ago

  40 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA

• 10/16/2019 - 5 years ago

  39 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP

• 8/22/2019 - 5 years ago

  38 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA

• 8/19/2019 - 5 years ago

  37 - EXTENSION 3 GRANTED Type: EX3G

• 8/19/2019 - 5 years ago

  36 - EXTENSION 3 FILED Type: EXT3

• 8/19/2019 - 5 years ago

  35 - TEAS EXTENSION RECEIVED Type: EEXT

• 2/19/2019 - 5 years ago

  34 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA

• 2/15/2019 - 5 years ago

  33 - EXTENSION 2 GRANTED Type: EX2G

• 2/15/2019 - 5 years ago

  32 - EXTENSION 2 FILED Type: EXT2

• 2/15/2019 - 5 years ago

  31 - TEAS EXTENSION RECEIVED Type: EEXT

• 9/21/2018 - 6 years ago

  30 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA

• 9/21/2018 - 6 years ago

  29 - CORRECTED NOA E-MAILED Type: NOAC

• 9/20/2018 - 6 years ago

  28 - EXTENSION 1 GRANTED Type: EX1G

• 8/20/2018 - 6 years ago

  27 - EXTENSION 1 FILED Type: EXT1

• 9/20/2018 - 6 years ago

  26 - DIVISIONAL PROCESSING COMPLETE Type: DPCC

• 8/20/2018 - 6 years ago

  25 - DIVISIONAL REQUEST RECEIVED Type: DRRR

• 9/17/2018 - 6 years ago

  24 - CASE ASSIGNED TO INTENT TO USE PARALEGAL Type: AITU

• 8/20/2018 - 6 years ago

  23 - TEAS REQUEST TO DIVIDE RECEIVED Type: ERTD

• 8/20/2018 - 6 years ago

  22 - TEAS EXTENSION RECEIVED Type: EEXT

• 2/26/2018 - 6 years ago

  21 - CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED Type: CHPB

• 2/20/2018 - 6 years ago

  20 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM

• 2/16/2018 - 6 years ago

  19 - ASSIGNED TO PETITION STAFF Type: APET

• 2/6/2018 - 6 years ago

  18 - TEAS POST PUBLICATION AMENDMENT RECEIVED Type: EPPA

• 12/26/2017 - 7 years ago

  17 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 12/26/2017 - 7 years ago

  16 - PUBLISHED FOR OPPOSITION Type: PUBO

• 12/6/2017 - 7 years ago

  15 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 11/14/2017 - 7 years ago

  14 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 11/14/2017 - 7 years ago

  13 - EXAMINER'S AMENDMENT ENTERED Type: XAEC

• 11/14/2017 - 7 years ago

  12 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN

• 11/14/2017 - 7 years ago

  11 - EXAMINERS AMENDMENT E-MAILED Type: GNEA

• 11/14/2017 - 7 years ago

  10 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA

• 11/9/2017 - 7 years ago

  9 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 11/8/2017 - 7 years ago

  8 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 11/8/2017 - 7 years ago

  7 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 7/24/2017 - 7 years ago

  6 - NOTIFICATION OF PRIORITY ACTION E-MAILED Type: GPRN

• 7/24/2017 - 7 years ago

  5 - PRIORITY ACTION E-MAILED Type: GPRA

• 7/24/2017 - 7 years ago

  4 - PRIORITY ACTION WRITTEN Type: CPRA

• 7/17/2017 - 7 years ago

  3 - ASSIGNED TO EXAMINER Type: DOCK

• 4/28/2017 - 7 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM Type: NWOS

• 4/25/2017 - 7 years ago

  1 - NEW APPLICATION ENTERED IN TRAM Type: NWAP